Rationale: Antiphospholipid syndrome (APS) combined with acute coronary syndrome (ACS) is rarely reported. Patient concerns: One male patient with APS was admitted to our hospital, who had recent unstable angina (UA). Diagnosis: The preliminary diagnosis of ACS and UA (BraunwaldiB) was then made. Interventions: This patient received secondary preventative therapy for coronary heart disease (CHD) in combination with percutaneous transluminal coronary angioplasty (PICA) and implantation of NeoVas Bioresorbable Coronary Scaffold. Outcomes: The patient was followed up, without new UA episodes were observed at 6 months, 1 year, and 2 year after surgery, respectively. Lessons: It was thus concluded that percutaneous coronary intervention (PCI) is effective for APS patients and NeoVas scaffold implantation is presumed safe.
基金:
National Program on Key Basic Research Project (973 Program)National Basic Research Program of China [2015CB554404]
第一作者机构:[1]Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
通讯作者:
通讯机构:[1]Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.[*1]Department of Cardiology, Beijing Anzhen Hospital, No. 2, Anzhen Road, Chaoyang District, Beijing 100029, China
推荐引用方式(GB/T 7714):
Yuan Shan,Ping Wang,JingHua Liu.Antiphospholipid syndrome combined with acute coronary syndrome Case report[J].MEDICINE.2018,97(51):-.doi:10.1097/MD.0000000000013613.
APA:
Yuan Shan,Ping Wang&JingHua Liu.(2018).Antiphospholipid syndrome combined with acute coronary syndrome Case report.MEDICINE,97,(51)
MLA:
Yuan Shan,et al."Antiphospholipid syndrome combined with acute coronary syndrome Case report".MEDICINE 97..51(2018):-